ENCE CHUCK (Chief Financial Officer) purchased 38.97K shares of RELMADA THERAPEUTICS, INC. on the open market
Open‑market purchase worth $150.9K. The strongest form of insider conviction signal.
P · 3 purchases
Filed: 1/31/2024ACC: 0001213900-24-008557
Officer· Chief Financial Officer
Since Jul 2019
+38.97K
Net shares
Net buyer
$150.9K
Total acquired
3
Open market trades
3B · 0S
3
Total transactions
38.97K acquired
Non-Derivative Transactions3
Common Stock
Direct
Shares
+10.80K
Price / share
$3.65
Trade value
$39.44K
% of position
New position
1/29/2024
0.00→10.80K
Common Stock
Direct
Shares
+14.50K
Price / share
$3.87
Trade value
$56.05K
% of position
134.3%
1/30/2024
10.80K→25.30K
Common Stock
Direct
Shares
+13.67K
Price / share
$4.05
Trade value
$55.43K
% of position
54.0%
1/31/2024
25.30K→38.97K
Total
Net shares
+38.97K
Net value
$150.92K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 1/29/2024 | P · Purchase | +10.80K | $3.65 | $39.44K | New position | 0.00 | 10.80K |
| Common Stock Direct | 1/30/2024 | P · Purchase | +14.50K | $3.87 | $56.05K | 134.3% | 10.80K | 25.30K |
| Common Stock Direct | 1/31/2024 | P · Purchase | +13.67K | $4.05 | $55.43K | 54.0% | 25.30K | 38.97K |
| Total | +38.97K | $150.92K | ||||||
Derivative Transactions0
No derivative transactions reported